{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:56:04Z","timestamp":1793451364929,"version":"4.5.0"},"reference-count":203,"publisher":"Georg Thieme Verlag KG","issue":"01","license":[{"start":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T00:00:00Z","timestamp":1636761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The consensus of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation (AF) has been published in 2017 which provided useful clinical guidance for cardiologists, neurologists, geriatricians, and general practitioners in the Asia-Pacific region. In these years, many important new data regarding stroke prevention in AF were reported. The practice guidelines subcommittee members comprehensively reviewed updated information on stroke prevention in AF, and summarized them in this 2021 focused update of the 2017 consensus guidelines of the APHRS on stroke prevention in AF. We highlighted and focused on several issues, including the importance of the AF Better Care pathway, the advantages of non-vitamin K antagonist oral anticoagulants (NOACs) for Asians, the considerations of use of NOACs for Asian AF patients with single one stroke risk factor beyond gender, the role of lifestyle factors on stroke risk, the use of oral anticoagulants during the \u201ccoronavirus disease 2019\u201d pandemic, etc. We fully realize that there are gaps, unaddressed questions, and many areas of uncertainty and debate in the current knowledge of AF, and the physician's decision remains the most important factor in the management of AF.<\/jats:p>","DOI":"10.1055\/s-0041-1739411","type":"journal-article","created":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T18:47:39Z","timestamp":1636829259000},"page":"020-047","source":"Crossref","is-referenced-by-count":406,"title":["2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary"],"prefix":"10.1055","volume":"122","author":[{"given":"Tze-Fan","family":"Chao","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan"},{"name":"Institute of Clinical Medicine and Cardiovascular Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyoung","family":"Joung","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihide","family":"Takahashi","sequence":"additional","affiliation":[{"name":"The Department of Advanced Arrhythmia Research, Tokyo Medical and Dental University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toon Wei","family":"Lim","sequence":"additional","affiliation":[{"name":"National University Heart Centre, National University Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eue-Keun","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsin","family":"Chan","sequence":"additional","affiliation":[{"name":"Microscopy Core Laboratory, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan, Taiwan"},{"name":"Microscopy Core Laboratory, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7626-7751","authenticated-orcid":false,"given":"Yutao","family":"Guo","sequence":"additional","affiliation":[{"name":"Pulmonary Vessel and Thrombotic Disease, Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charn","family":"Sriratanasathavorn","sequence":"additional","affiliation":[{"name":"Her Majesty Cardiac Center, Siriraj, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seil","family":"Oh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Okumura","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Saiseikai Kumamoto Hospital, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-1626","authenticated-orcid":false,"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool & Liverpool Heart and Chest Hospital, Liverpool, United Kingdom"},{"name":"Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,11,13]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccep.2020.10.010","article-title":"Epidemiology of atrial fibrillation: geographic\/ecological risk factors, age, sex, genetics","volume":"13","author":"J Zhang","year":"2021","journal-title":"Card Electrophysiol Clin"},{"issue":"02","key":"ref2","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.chest.2017.10.001","article-title":"Lifetime risks, projected numbers, and adverse outcomes in Asian patients with atrial fibrillation: a report from the Taiwan nationwide AF cohort study","volume":"153","author":"T F Chao","year":"2018","journal-title":"Chest"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ahj.2018.04.017","article-title":"10-year nationwide trends of the incidence, prevalence, and adverse outcomes of non-valvular atrial fibrillation nationwide health insurance data covering the entire Korean population","volume":"202","author":"D Kim","year":"2018","journal-title":"Am Heart J"},{"issue":"04","key":"ref4","first-page":"810","article-title":"The global burden of atrial fibrillation and stroke: a systematic review of the clinical epidemiology of atrial fibrillation in Asia","volume":"152","author":"Y Bai","year":"2017","journal-title":"Chest"},{"issue":"14","key":"ref5","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1161\/CIRCULATIONAHA.118.036046","article-title":"Evolving changes of the use of oral anticoagulants and outcomes in patients with newly diagnosed atrial fibrillation in Taiwan","volume":"138","author":"T F Chao","year":"2018","journal-title":"Circulation"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2021.06.051","article-title":"2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation","author":"T F Chao","year":"2021","journal-title":"J Arrhythm"},{"issue":"11","key":"ref7","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrcardio.2017.153","article-title":"The ABC pathway: an integrated approach to improve AF management","volume":"14","author":"G YH Lip","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1055\/a-1515-9630","article-title":"Adherence to the \u2018Atrial Fibrillation Better Care\u2019 pathway in patients with atrial fibrillation: impact on clinical outcomes-a systematic review and meta-analysis of 285,000 patients","author":"G F Romiti","year":"2021","journal-title":"Thromb Haemost"},{"issue":"05","key":"ref9","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report","volume":"154","author":"G YH Lip","year":"2018","journal-title":"Chest"},{"issue":"12","key":"ref10","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.4070\/kcj.2018.0339","article-title":"2018 Korean guideline of atrial fibrillation management","volume":"48","author":"B Joung","year":"2018","journal-title":"Korean Circ J"},{"issue":"05","key":"ref11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"G Hindricks","year":"2021","journal-title":"Eur Heart J"},{"issue":"04","key":"ref12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.joa.2017.05.004","article-title":"2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation","volume":"33","author":"C E Chiang","year":"2017","journal-title":"J Arrhythm"},{"issue":"16","key":"ref13","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.jacc.2014.06.1203","article-title":"Using the CHA2DS2-VASc score for refining stroke risk stratification in \u2018low-risk\u2019 Asian patients with atrial fibrillation","volume":"64","author":"T F Chao","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ijcard.2015.05.115","article-title":"The CHADS2 and CHA2DS2-VASc scores for predicting ischemic stroke among East Asian patients with atrial fibrillation: a systemic review and meta-analysis","volume":"195","author":"Q Xiong","year":"2015","journal-title":"Int J Cardiol"},{"issue":"01","key":"ref15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.hrthm.2015.08.017","article-title":"Comparisons of CHADS2 and CHA2DS2-VASc scores for stroke risk stratification in atrial fibrillation: which scoring system should be used for Asians?","volume":"13","author":"T F Chao","year":"2016","journal-title":"Heart Rhythm"},{"issue":"08","key":"ref16","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1253\/circj.CJ-16-1267","article-title":"Risk of ischemic stroke in patients with non-valvular atrial fibrillation not receiving oral anticoagulants - Korean nationwide population-based study","volume":"81","author":"S H Kang","year":"2017","journal-title":"Circ J"},{"issue":"06","key":"ref17","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1161\/STROKEAHA.117.016926","article-title":"CHA2DS2-VASc score (congestive heart failure, hypertension, age \u226575 [doubled], diabetes mellitus, prior stroke or transient ischemic attack [doubled], vascular disease, age 65-74, female) for stroke in Asian patients with atrial fibrillation: a Korean nationwide sample cohort study","volume":"48","author":"T H Kim","year":"2017","journal-title":"Stroke"},{"issue":"11","key":"ref18","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1161\/STROKEAHA.117.018551","article-title":"CHA2DS2-VASc score for identifying truly low-risk atrial fibrillation for stroke: a Korean nationwide cohort study","volume":"48","author":"T H Kim","year":"2017","journal-title":"Stroke"},{"issue":"10","key":"ref19","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1093\/europace\/euab087","article-title":"A meta-analysis of clinical risk factors for stroke in anticoagulant-na\u00efve patients with atrial fibrillation","volume":"23","author":"J J Noubiap","year":"2021","journal-title":"Europace"},{"issue":"19","key":"ref20","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1093\/eurheartj\/ehy837","article-title":"Age threshold for the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation: insights into the optimal assessment of age and incident comorbidities","volume":"40","author":"T F Chao","year":"2019","journal-title":"Eur Heart J"},{"issue":"08","key":"ref21","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1161\/STROKEAHA.118.021047","article-title":"Age threshold for ischemic stroke risk in atrial fibrillation","volume":"49","author":"T H Kim","year":"2018","journal-title":"Stroke"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"27410","DOI":"10.1038\/srep27410","article-title":"Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: a nationwide cohort study","volume":"6","author":"P B Nielsen","year":"2016","journal-title":"Sci Rep"},{"issue":"05","key":"ref23","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.cjca.2019.01.018","article-title":"Importance of risk reassessment in patients with atrial fibrillation in guidelines: assessing risk as a dynamic process","volume":"35","author":"T Y Chang","year":"2019","journal-title":"Can J Cardiol"},{"issue":"02","key":"ref24","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jacc.2017.10.085","article-title":"Relationship of aging and incident comorbidities to stroke risk in patients with atrial fibrillation","volume":"71","author":"T F Chao","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"09","key":"ref25","doi-asserted-by":"crossref","first-page":"663","DOI":"10.7326\/M18-1177","article-title":"Reassessment of risk for stroke during follow-up of patients with atrial fibrillation","volume":"170","author":"T F Chao","year":"2019","journal-title":"Ann Intern Med"},{"issue":"07","key":"ref26","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1055\/s-0038-1651482","article-title":"Dynamic changes of CHA2DS2-VASc score and the risk of ischaemic stroke in asian patients with atrial fibrillation: a nationwide cohort study","volume":"118","author":"M Yoon","year":"2018","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/jcm9041234","article-title":"Incident comorbidities, aging and the risk of stroke in 608,108 patients with atrial fibrillation: a nationwide analysis","volume":"9","author":"L Fauchier","year":"2020","journal-title":"J Clin Med"},{"issue":"07","key":"ref28","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1055\/s-0039-1683933","article-title":"Incident co-morbidities in patients with atrial fibrillation initially with a CHA2DS2-VASc score of 0 (males) or 1 (females): implications for reassessment of stroke risk in initially \u2018low-risk\u2019 patients","volume":"119","author":"T F Chao","year":"2019","journal-title":"Thromb Haemost"},{"issue":"12","key":"ref29","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1055\/s-0038-1675400","article-title":"Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review","volume":"118","author":"E D Borre","year":"2018","journal-title":"Thromb Haemost"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1093\/ehjqcco\/qcab069","article-title":"Comparison of HAS-BLED and ORBIT bleeding risk scores in AF patients treated with NOACs: a report from the ESC-EHRA EORP-AF general long-term registry","author":"M Proietti","year":"2021","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"02","key":"ref31","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.amjmed.2017.09.009","article-title":"Comparing bleeding risk assessment focused on modifiable risk factors only versus validated bleeding risk scores in atrial fibrillation","volume":"131","author":"Y Guo","year":"2018","journal-title":"Am J Med"},{"issue":"04","key":"ref32","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1055\/s-0038-1636534","article-title":"Incident risk factors and major bleeding in patients with atrial fibrillation treated with oral anticoagulants: a comparison of baseline, follow-up and delta HAS-BLED scores with an approach focused on modifiable bleeding risk factors","volume":"118","author":"T F Chao","year":"2018","journal-title":"Thromb Haemost"},{"issue":"13","key":"ref33","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.jacc.2020.01.052","article-title":"Mobile health technology to improve care for patients with atrial fibrillation","volume":"75","author":"Y Guo","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"ref34","first-page":"1195.e2","article-title":"Regular bleeding risk assessment associated with reduction in bleeding outcomes: the mAFA-II randomized trial","volume":"133","author":"Y Guo","year":"2020","journal-title":"Am J Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-021-01816-z","article-title":"Continuation or discontinuation of oral anticoagulants after HAS-BLED scores increase in patients with atrial fibrillation","author":"T F Chao","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1093\/ehjqcco\/qcab050","article-title":"Should oral anticoagulants still be prescribed to patients with atrial fibrillation with a single stroke risk factor but at high bleeding risk? a nationwide cohort study","author":"T F Chao","year":"2021","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"12","key":"ref37","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1160\/TH-17-10-0709","article-title":"Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: executive summary of a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulaci\u00f3n Card\u00edaca y Electrofisiolog\u00eda (SOLEACE)","volume":"117","author":"G YH Lip","year":"2017","journal-title":"Thromb Haemost"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial","volume":"367","author":"S Connolly","year":"2006","journal-title":"Lancet"},{"issue":"12","key":"ref39","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"S J Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"09","key":"ref40","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"S J Connolly","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"ref41","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"C B Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"07","key":"ref42","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.tcm.2019.02.008","article-title":"Recommendations on stroke prevention for patients having a CHA2DS2-VASc score of 1 (males) or 2 (females) in 2019 atrial fibrillation guidelines","volume":"29","author":"T F Chao","year":"2019","journal-title":"Trends Cardiovasc Med"},{"issue":"07","key":"ref43","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jacc.2014.11.046","article-title":"Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?","volume":"65","author":"T F Chao","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"ref44","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.jacc.2015.07.026","article-title":"Age threshold for increased stroke risk among patients with atrial fibrillation: a nationwide cohort study from Taiwan","volume":"66","author":"T F Chao","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"05","key":"ref45","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.chest.2019.11.025","article-title":"Comparing the effectiveness and safety of nonvitamin K antagonist oral anticoagulants and warfarin in elderly asian patients with atrial fibrillation: a nationwide cohort study","volume":"157","author":"T F Chao","year":"2020","journal-title":"Chest"},{"issue":"08","key":"ref46","doi-asserted-by":"crossref","first-page":"668","DOI":"10.4070\/kcj.2021.0170","article-title":"Stroke and bleeding risk assessment in atrial fibrillation: where are we now?","volume":"51","author":"L Kuo","year":"2021","journal-title":"Korean Circ J"},{"issue":"03","key":"ref47","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3349\/ymj.2019.60.3.277","article-title":"Label adherence for non-vitamin K antagonist oral anticoagulants in a prospective cohort of Asian patients with atrial fibrillation","volume":"60","author":"S R Lee","year":"2019","journal-title":"Yonsei Med J"},{"issue":"05","key":"ref48","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1161\/STROKEAHA.118.024210","article-title":"Optimal rivaroxaban dose in Asian patients with atrial fibrillation and normal or mildly impaired renal function","volume":"50","author":"S R Lee","year":"2019","journal-title":"Stroke"},{"issue":"09","key":"ref49","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1161\/STROKEAHA.119.025623","article-title":"Low-dose rivaroxaban and risks of adverse events in patients with atrial fibrillation","volume":"50","author":"W H Cheng","year":"2019","journal-title":"Stroke"},{"issue":"12","key":"ref50","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1016\/j.hrthm.2020.07.022","article-title":"Off-label dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation","volume":"17","author":"Y H Chan","year":"2020","journal-title":"Heart Rhythm"},{"issue":"12","key":"ref51","doi-asserted-by":"crossref","first-page":"e014177","DOI":"10.1161\/JAHA.119.014177","article-title":"Label adherence of direct oral anticoagulants dosing and clinical outcomes in patients with atrial fibrillation","volume":"9","author":"H T Yu","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"05","key":"ref52","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/ehjcvp\/pvab004","article-title":"Off-label underdosed apixaban use in Asian patients with non-valvular atrial fibrillation","volume":"7","author":"S R Lee","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"04","key":"ref53","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/europace\/euz273","article-title":"The optimal drug adherence to maximize the efficacy and safety of non-vitamin K antagonist oral anticoagulant in real-world atrial fibrillation patients","volume":"22","author":"D Kim","year":"2020","journal-title":"Europace"},{"issue":"01","key":"ref54","first-page":"99","article-title":"A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF)","volume":"35","author":"H Kim","year":"2020","journal-title":"Korean J Intern Med (Korean Assoc Intern Med)"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1093\/ehjqcco\/qcab057","article-title":"Quality indicators in the management of elderly Chinese patients with atrial fibrillation: a report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry","author":"Y Guo","year":"2021","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"03","key":"ref56","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1055\/s-0039-3401823","article-title":"Lower versus standard INR targets in atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials","volume":"120","author":"A K Pandey","year":"2020","journal-title":"Thromb Haemost"},{"issue":"11","key":"ref57","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1161\/01.STR.31.11.2558","article-title":"Prediction of functional outcome and in-hospital mortality after admission with oral anticoagulant-related intracerebral hemorrhage","volume":"31","author":"J Berwaerts","year":"2000","journal-title":"Stroke"},{"issue":"02","key":"ref58","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCOUTCOMES.108.796185","article-title":"Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review","volume":"1","author":"Y Wan","year":"2008","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ijcard.2016.04.131","article-title":"Relation of the SAMe-TT2R2 score to quality of anticoagulation control and thromboembolic events in atrial fibrillation patients: observations from the SPORTIF trials","volume":"216","author":"M Proietti","year":"2016","journal-title":"Int J Cardiol"},{"issue":"03","key":"ref60","doi-asserted-by":"crossref","first-page":"e0150674","DOI":"10.1371\/journal.pone.0150674","article-title":"Use of the SAMe-TT2R2 score to predict good anticoagulation control with warfarin in chinese patients with atrial fibrillation: relationship to ischemic stroke incidence","volume":"11","author":"P H Chan","year":"2016","journal-title":"PLoS One"},{"issue":"11","key":"ref61","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.amjmed.2015.05.036","article-title":"The SAMe-TT2R2 score predicts poor anticoagulation control in AF patients: a prospective \u2018real-world\u2019 inception cohort study","volume":"128","author":"V Rold\u00e1n","year":"2015","journal-title":"Am J Med"},{"issue":"11","key":"ref62","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.amjmed.2014.05.023","article-title":"SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation","volume":"127","author":"P Gallego","year":"2014","journal-title":"Am J Med"},{"issue":"05","key":"ref63","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1378\/chest.13-0054","article-title":"Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score","volume":"144","author":"S Apostolakis","year":"2013","journal-title":"Chest"},{"issue":"10","key":"ref64","doi-asserted-by":"crossref","first-page":"e051987","DOI":"10.1136\/bmjopen-2021-051987","article-title":"Prospective randomised trial examining the impact of an educational intervention versus usual care on anticoagulation therapy control based on an SAMe-TT2R2 score-guided strategy in anticoagulant-na\u00efve Thai patients with atrial fibrillation (TREATS-AF): a study protocol","volume":"11","author":"A Phrommintikul","year":"2021","journal-title":"BMJ Open"},{"issue":"09","key":"ref65","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1161\/STROKEAHA.115.009947","article-title":"Non-vitamin K antagonist oral anticoagulants for stroke prevention in Asian patients with nonvalvular atrial fibrillation: meta-analysis","volume":"46","author":"K L Wang","year":"2015","journal-title":"Stroke"},{"issue":"09","key":"ref66","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.amjcard.2017.07.050","article-title":"Meta-analysis of efficacy and safety of low-intensity warfarin therapy for East Asian patients with nonvalvular atrial fibrillation","volume":"120","author":"T Liu","year":"2017","journal-title":"Am J Cardiol"},{"issue":"02","key":"ref67","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1253\/circj.CJ-14-1057","article-title":"Target intensity of anticoagulation with warfarin in Japanese patients with valvular atrial fibrillation \u2013 subanalysis of the J-RHYTHM registry","volume":"79","author":"E Kodani","year":"2015","journal-title":"Circ J"},{"issue":"03","key":"ref68","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1055\/s-0040-1702230","article-title":"Should we adopt a standard international normalized ratio range of 2.0 to 3.0 for Asian patients with atrial fibrillation? An appeal for evidence-based management, not eminence-based recommendations","volume":"120","author":"T F Chao","year":"2020","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref69","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1055\/s-0038-1676835","article-title":"Improving the prescription of oral anticoagulants in atrial fibrillation: a systematic review","volume":"119","author":"R V Pritchett","year":"2019","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref70","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1055\/s-0039-1697954","article-title":"NOAC adherence of patients with atrial fibrillation in the real world: dosing frequency matters?","volume":"120","author":"J Hwang","year":"2020","journal-title":"Thromb Haemost"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"C T Ruff","year":"2014","journal-title":"Lancet"},{"issue":"19","key":"ref73","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/eurheartj\/ehy807","article-title":"Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial","volume":"40","author":"T F Chao","year":"2019","journal-title":"Eur Heart J"},{"issue":"06","key":"ref74","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s10557-019-06910-z","article-title":"Real-world comparisons of direct oral anticoagulants for stroke prevention in asian patients with non-valvular atrial fibrillation: a systematic review and meta-analysis","volume":"33","author":"Y H Chan","year":"2019","journal-title":"Cardiovasc Drugs Ther"},{"issue":"01","key":"ref75","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/CIRCULATIONAHA.117.031658","article-title":"Oral anticoagulation in very elderly patients with atrial fibrillation: a nationwide cohort study","volume":"138","author":"T F Chao","year":"2018","journal-title":"Circulation"},{"issue":"08","key":"ref76","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2018.11.051","article-title":"Direct oral anticoagulants in patients with nonvalvular atrial fibrillation and low body weight","volume":"73","author":"S R Lee","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"ref77","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1016\/j.jacc.2019.04.052","article-title":"Direct oral anticoagulants in patients with atrial fibrillation and liver disease","volume":"73","author":"S R Lee","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"06","key":"ref78","first-page":"6","article-title":"Liver cirrhosis in patients with atrial fibrillation: would oral anticoagulation have a net clinical benefit for stroke prevention?","volume":"6","author":"L Kuo","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ahj.2020.08.006","article-title":"Non-vitamin K antagonist oral anticoagulants in very elderly east Asians with atrial fibrillation: a nationwide population-based study","volume":"229","author":"S Kwon","year":"2020","journal-title":"Am Heart J"},{"issue":"06","key":"ref80","doi-asserted-by":"crossref","first-page":"e13488","DOI":"10.1111\/eci.13488","article-title":"Non-vitamin K antagonist oral anticoagulants versus warfarin in AF patients \u2265 85 years","volume":"51","author":"C T Tsai","year":"2021","journal-title":"Eur J Clin Invest"},{"issue":"23","key":"ref81","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/j.jacc.2017.03.600","article-title":"Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction","volume":"69","author":"X Yao","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.jacc.2017.04.045","article-title":"When less is not more","volume":"69","author":"S D Pokorney","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"ref83","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/eurheartj\/ehy802","article-title":"Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials","volume":"40","author":"K L Wang","year":"2019","journal-title":"Eur Heart J"},{"issue":"08","key":"ref84","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1253\/circj.CJ-21-0399","article-title":"Optimal management of anticoagulation therapy in Asian patients with atrial fibrillation","volume":"85","author":"W H Cheng","year":"2021","journal-title":"Circ J"},{"issue":"15","key":"ref85","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.jacc.2020.08.025","article-title":"Impacts of different renal function estimation formulas on dosing of DOACs and clinical outcomes","volume":"76","author":"Y H Chan","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"ref86","doi-asserted-by":"crossref","first-page":"e013053","DOI":"10.1161\/JAHA.119.013053","article-title":"Comparisons of rivaroxaban following different dosage criteria (ROCKET AF or J-ROCKET AF trials) in Asian patients with atrial fibrillation","volume":"8","author":"Y H Chan","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"ref87","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1161\/CIRCINTERVENTIONS.116.004395","article-title":"Antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a North American Perspective-2016 update","volume":"9","author":"D J Angiolillo","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"issue":"01","key":"ref88","doi-asserted-by":"crossref","first-page":"e0209593","DOI":"10.1371\/journal.pone.0209593","article-title":"Temporal trends in prevalence and antithrombotic treatment among Asians with atrial fibrillation undergoing percutaneous coronary intervention: a nationwide Korean population-based study","volume":"14","author":"J Park","year":"2019","journal-title":"PLoS One"},{"issue":"05","key":"ref89","doi-asserted-by":"crossref","first-page":"409","DOI":"10.4070\/kcj.2020.0407","article-title":"Impact of non-vitamin K antagonist oral anticoagulants on the change of antithrombotic regimens in patients with atrial fibrillation undergoing percutaneous coronary intervention","volume":"51","author":"S Kwon","year":"2021","journal-title":"Korean Circ J"},{"issue":"09","key":"ref90","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/14779072.2020.1808463","article-title":"Antithrombotic treatment in atrial fibrillation patients undergoing percutaneous coronary interventions: focus on stent thrombosis","volume":"18","author":"M Vitolo","year":"2020","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"04","key":"ref91","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-0040-1718729","article-title":"The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease","volume":"121","author":"H K Kim","year":"2021","journal-title":"Thromb Haemost"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"W J Dewilde","year":"2013","journal-title":"Lancet"},{"issue":"25","key":"ref93","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"C M Gibson","year":"2016","journal-title":"N Engl J Med"},{"issue":"16","key":"ref94","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"C P Cannon","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"ref95","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"R D Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"P Vranckx","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"ref97","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/eurheartj\/ehz059","article-title":"Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial","volume":"40","author":"J Oldgren","year":"2019","journal-title":"Eur Heart J"},{"issue":"10","key":"ref98","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"J Steffel","year":"2021","journal-title":"Europace"},{"issue":"06","key":"ref99","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.amjcard.2019.05.072","article-title":"Meta-analysis of oral anticoagulant monotherapy as an antithrombotic strategy in patients with stable coronary artery disease and nonvalvular atrial fibrillation","volume":"124","author":"S R Lee","year":"2019","journal-title":"Am J Cardiol"},{"issue":"12","key":"ref100","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","article-title":"Antithrombotic therapy for atrial fibrillation with stable coronary disease","volume":"381","author":"S Yasuda","year":"2019","journal-title":"N Engl J Med"},{"issue":"25","key":"ref101","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1161\/CIRCULATIONAHA.113.006426","article-title":"Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial","volume":"129","author":"L Di Biase","year":"2014","journal-title":"Circulation"},{"issue":"10","key":"ref102","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1016\/j.hrthm.2017.05.012","article-title":"2017 HRS\/EHRA\/ECAS\/APHRS\/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation","volume":"14","author":"H Calkins","year":"2017","journal-title":"Heart Rhythm"},{"issue":"04","key":"ref103","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/joa3.12081","article-title":"Influence of substrate modification in catheter ablation of atrial fibrillation on the incidence of acute complications: analysis of 10 795 procedures in J-CARAF Study 2011-2016","volume":"34","author":"Y Murakawa","year":"2018","journal-title":"J Arrhythm"},{"issue":"10","key":"ref104","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/europace\/eut241","article-title":"Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature","volume":"15","author":"S H Hohnloser","year":"2013","journal-title":"Europace"},{"issue":"28","key":"ref105","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1093\/eurheartj\/ehv177","article-title":"Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation","volume":"36","author":"R Cappato","year":"2015","journal-title":"Eur Heart J"},{"issue":"17","key":"ref106","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1701005","article-title":"Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation","volume":"376","author":"H Calkins","year":"2017","journal-title":"N Engl J Med"},{"issue":"32","key":"ref107","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1093\/eurheartj\/ehy176","article-title":"Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation","volume":"39","author":"P Kirchhof","year":"2018","journal-title":"Eur Heart J"},{"issue":"36","key":"ref108","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1093\/eurheartj\/ehz190","article-title":"Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial","volume":"40","author":"S H Hohnloser","year":"2019","journal-title":"Eur Heart J"},{"key":"ref109","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijcard.2018.06.024","article-title":"A meta-analysis of randomized controlled trials of uninterrupted periprocedural anticoagulation strategy in patients undergoing atrial fibrillation catheter ablation","volume":"270","author":"Y Zhao","year":"2018","journal-title":"Int J Cardiol"},{"issue":"01","key":"ref110","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.hrthm.2017.09.011","article-title":"An updated meta-analysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupted anticoagulation in atrial fibrillation catheter ablation","volume":"15","author":"R Cardoso","year":"2018","journal-title":"Heart Rhythm"},{"issue":"02","key":"ref111","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/europace\/euy148","article-title":"Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events","volume":"21","author":"K Nakamura","year":"2019","journal-title":"Europace"},{"issue":"19","key":"ref112","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1093\/eurheartj\/ehy870","article-title":"When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study","volume":"40","author":"H T Yu","year":"2019","journal-title":"Eur Heart J"},{"issue":"04","key":"ref113","doi-asserted-by":"crossref","first-page":"e191994","DOI":"10.1001\/jamanetworkopen.2019.1994","article-title":"Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial","volume":"2","author":"A Nogami","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"10","key":"ref114","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1253\/circj.CJ-19-0535","article-title":"Efficacy and safety of uninterrupted periprocedural edoxaban in patients undergoing catheter ablation for atrial fibrillation - the prospective KYU-RABLE study","volume":"83","author":"N Takahashi","year":"2019","journal-title":"Circ J"},{"issue":"18","key":"ref115","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2012-11-468207","article-title":"A specific antidote for dabigatran: functional and structural characterization","volume":"121","author":"F Schiele","year":"2013","journal-title":"Blood"},{"issue":"06","key":"ref116","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"C V Pollack Jr","year":"2015","journal-title":"N Engl J Med"},{"issue":"05","key":"ref117","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal - full cohort analysis","volume":"377","author":"C V Pollack Jr","year":"2017","journal-title":"N Engl J Med"},{"issue":"14","key":"ref118","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.jacc.2019.07.070","article-title":"Dabigatran reversal with idarucizumab in patients with renal impairment","volume":"74","author":"J W Eikelboom","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"01","key":"ref119","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-0039-1695771","article-title":"Global use of idarucizumab in clinical practice: outcomes of the RE-VECTO surveillance program","volume":"120","author":"J Fanikos","year":"2020","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref120","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.3102","article-title":"A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa","volume":"19","author":"G Lu","year":"2013","journal-title":"Nat Med"},{"issue":"25","key":"ref121","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","article-title":"Andexanet alfa for the reversal of factor Xa inhibitor activity","volume":"373","author":"D M Siegal","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"ref122","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"S J Connolly","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"ref123","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.hrthm.2020.05.026","article-title":"Risks and outcomes of gastrointestinal malignancies in anticoagulated atrial fibrillation patients experiencing gastrointestinal bleeding: a nationwide cohort study","volume":"17","author":"T Y Chang","year":"2020","journal-title":"Heart Rhythm"},{"issue":"02","key":"ref124","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1253\/circj.CJ-16-0917","article-title":"Clinical significance of hematuria in atrial fibrillation with oral anticoagulation therapy","volume":"81","author":"H T Yu","year":"2017","journal-title":"Circ J"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euz258","article-title":"EHRA\/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update","author":"M Glikson","year":"2019","journal-title":"Europace"},{"issue":"22","key":"ref126","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1056\/NEJMoa2101897","article-title":"Left atrial appendage occlusion during cardiac surgery to prevent stroke","volume":"384","author":"R P Whitlock","year":"2021","journal-title":"N Engl J Med"},{"key":"ref127","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0140-6736(09)61343-X","article-title":"Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial","volume":"374","author":"D R Holmes","year":"2009","journal-title":"Lancet"},{"issue":"01","key":"ref128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","article-title":"Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial","volume":"64","author":"D R Holmes Jr","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"04","key":"ref129","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1161\/CIRCULATIONAHA.110.976449","article-title":"Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry","volume":"123","author":"V Y Reddy","year":"2011","journal-title":"Circulation"},{"issue":"24","key":"ref130","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1016\/j.jacc.2015.04.025","article-title":"Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis","volume":"65","author":"D R Holmes Jr","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ahj.2016.10.003","article-title":"Interventional left atrial appendage closure vs novel anticoagulation agents in patients with atrial fibrillation indicated for long-term anticoagulation (PRAGUE-17 study)","volume":"183","author":"P Osmancik","year":"2017","journal-title":"Am Heart J"},{"issue":"25","key":"ref132","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1016\/j.jacc.2020.04.067","article-title":"Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation","volume":"75","author":"P Osmancik","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"09","key":"ref133","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.hrthm.2017.05.038","article-title":"Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-year follow-up outcome data of the EWOLUTION trial","volume":"14","author":"L V Boersma","year":"2017","journal-title":"Heart Rhythm"},{"issue":"01","key":"ref134","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10840-018-0351-1","article-title":"Percutaneous left atrial appendage closure with WATCHMAN\u2122 device: peri-procedural and mid-term outcomes from the TRAPS registry","volume":"52","author":"P Mazzone","year":"2018","journal-title":"J Interv Card Electrophysiol"},{"issue":"04","key":"ref135","doi-asserted-by":"crossref","first-page":"e006841","DOI":"10.1161\/CIRCEP.118.006841","article-title":"Evaluating real-world clinical outcomes in atrial fibrillation patients receiving the WATCHMAN left atrial appendage closure technology: final 2-year outcome data of the EWOLUTION trial focusing on history of stroke and hemorrhage","volume":"12","author":"L V Boersma","year":"2019","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"12","key":"ref136","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1253\/circj.CJ-18-0222","article-title":"Percutaneous WATCHMAN left atrial appendage closure for Japanese patients with nonvalvular atrial fibrillation at increased risk of thromboembolism - first results from the SALUTE trial","volume":"82","author":"K Aonuma","year":"2018","journal-title":"Circ J"},{"key":"ref137","first-page":"100358","article-title":"Left atrial appendage closure with WATCHMAN in Asian patients: 2\u03bcyear outcomes from the WASP registry","volume":"23","author":"K P Phillips","year":"2019","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"03","key":"ref138","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jcin.2013.11.010","article-title":"Percutaneous left atrial appendage occlusion for stroke prophylaxis in nonvalvular atrial fibrillation: a systematic review and analysis of observational studies","volume":"7","author":"N S Bajaj","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"issue":"01","key":"ref139","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1161\/CIRCEP.114.001413","article-title":"Utilization and adverse outcomes of percutaneous left atrial appendage closure for stroke prevention in atrial fibrillation in the United States: influence of hospital volume","volume":"8","author":"A O Badheka","year":"2015","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"05","key":"ref140","doi-asserted-by":"crossref","first-page":"E111","DOI":"10.1002\/ccd.26903","article-title":"Device-associated thrombus formation after left atrial appendage occlusion: a systematic review of events reported with the Watchman, the Amplatzer Cardiac Plug and the Amulet","volume":"90","author":"M Lempereur","year":"2017","journal-title":"Catheter Cardiovasc Interv"},{"issue":"14","key":"ref141","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1016\/j.jacc.2018.01.076","article-title":"Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation","volume":"71","author":"L Fauchier","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"ref142","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.jacc.2019.03.468","article-title":"Major adverse events with percutaneous left atrial appendage closure in patients with atrial fibrillation","volume":"73","author":"L Fauchier","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"05","key":"ref143","doi-asserted-by":"crossref","first-page":"e010195","DOI":"10.1161\/CIRCINTERVENTIONS.120.010195","article-title":"Device-related thrombus after left atrial appendage closure: data on thrombus characteristics, treatment strategies, and clinical outcomes from the EUROC-DRT-registry","volume":"14","author":"A Sedaghat","year":"2021","journal-title":"Circ Cardiovasc Interv"},{"key":"ref144","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ahj.2017.03.007","article-title":"The Assessment of the Watchman Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO) trial","volume":"189","author":"D R Holmes","year":"2017","journal-title":"Am Heart J"},{"issue":"24","key":"ref145","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1016\/j.jacc.2015.09.084","article-title":"Time to cost-effectiveness following stroke reduction strategies in AF: warfarin versus NOACs versus LAA closure","volume":"66","author":"V Y Reddy","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"ref146","doi-asserted-by":"crossref","first-page":"e011577","DOI":"10.1161\/JAHA.118.011577","article-title":"Cost-effectiveness of left atrial appendage closure for stroke reduction in atrial fibrillation: analysis of pooled, 5-year, long-term data","volume":"8","author":"V Y Reddy","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"09","key":"ref147","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jacc.2015.06.488","article-title":"Impact of CARDIOrespiratory FITness on arrhythmia recurrence in obese individuals with atrial fibrillation: the CARDIO-FIT study","volume":"66","author":"R K Pathak","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"ref148","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.jacc.2014.09.028","article-title":"Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study","volume":"64","author":"R K Pathak","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"ref149","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2015.03.002","article-title":"Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY)","volume":"65","author":"R K Pathak","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"04","key":"ref150","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1093\/europace\/euaa340","article-title":"Effect of alcohol consumption on the risk of adverse events in atrial fibrillation: from the COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF) registry","volume":"23","author":"C Lim","year":"2021","journal-title":"Europace"},{"issue":"09","key":"ref151","doi-asserted-by":"crossref","first-page":"794","DOI":"10.4070\/kcj.2019.0212","article-title":"Risk factor management for atrial fibrillation","volume":"49","author":"B Joung","year":"2019","journal-title":"Korean Circ J"},{"issue":"10","key":"ref152","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1093\/eurheartj\/ehy877","article-title":"Effect of hypertension duration and blood pressure level on ischaemic stroke risk in atrial fibrillation: nationwide data covering the entire Korean population","volume":"40","author":"T H Kim","year":"2019","journal-title":"Eur Heart J"},{"issue":"11","key":"ref153","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jacc.2018.05.076","article-title":"Ideal blood pressure in patients with atrial fibrillation","volume":"72","author":"D Kim","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"34","key":"ref154","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1093\/eurheartj\/ehx316","article-title":"Clinical implication of an impaired fasting glucose and prehypertension related to new onset atrial fibrillation in a healthy Asian population without underlying disease: a nationwide cohort study in Korea","volume":"38","author":"S S Lee","year":"2017","journal-title":"Eur Heart J"},{"issue":"01","key":"ref155","doi-asserted-by":"crossref","first-page":"19224","DOI":"10.1038\/s41598-020-75822-y","article-title":"Association between clustering of unhealthy lifestyle factors and risk of new-onset atrial fibrillation: a nationwide population-based study","volume":"10","author":"S R Lee","year":"2020","journal-title":"Sci Rep"},{"key":"ref156","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2020-318858","article-title":"Association of cardiovascular health and incident atrial fibrillation in elderly population","author":"J H Lee","year":"2021","journal-title":"Heart"},{"issue":"20","key":"ref157","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1001\/jama.292.20.2471","article-title":"Obesity and the risk of new-onset atrial fibrillation","volume":"292","author":"T J Wang","year":"2004","journal-title":"JAMA"},{"issue":"06","key":"ref158","first-page":"6","article-title":"Associations of abdominal obesity and new-onset atrial fibrillation in the general population","volume":"6","author":"Y S Baek","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"19","key":"ref159","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1001\/jama.2013.280521","article-title":"Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial","volume":"310","author":"H S Abed","year":"2013","journal-title":"JAMA"},{"issue":"02","key":"ref160","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.mayocp.2018.10.019","article-title":"Body mass index variability and long-term risk of new-onset atrial fibrillation in the general population: a Korean nationwide cohort study","volume":"94","author":"Y M Lim","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"ref161","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1093\/europace\/euy117","article-title":"PREVEntion and regReSsive Effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study","volume":"20","author":"M E Middeldorp","year":"2018","journal-title":"Europace"},{"key":"ref162","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijcard.2016.04.036","article-title":"Underweight is a risk factor for atrial fibrillation: a nationwide population-based study","volume":"215","author":"S H Kang","year":"2016","journal-title":"Int J Cardiol"},{"issue":"03","key":"ref163","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.hrthm.2019.09.029","article-title":"Bodyweight fluctuation is associated with increased risk of incident atrial fibrillation","volume":"17","author":"H J Lee","year":"2020","journal-title":"Heart Rhythm"},{"issue":"07","key":"ref164","doi-asserted-by":"crossref","first-page":"640.e9","DOI":"10.1016\/j.amjmed.2012.11.024","article-title":"Body mass index and adverse events in patients with incident atrial fibrillation","volume":"126","author":"T F Overvad","year":"2013","journal-title":"Am J Med"},{"issue":"04","key":"ref165","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1161\/STROKEAHA.116.015984","article-title":"Is there an obesity paradox for outcomes in atrial fibrillation? A systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant trials","volume":"48","author":"M Proietti","year":"2017","journal-title":"Stroke"},{"issue":"02","key":"ref166","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1161\/STROKEAHA.120.030356","article-title":"Body mass index and clinical outcomes in asian patients with atrial fibrillation receiving oral anticoagulation","volume":"52","author":"S R Lee","year":"2021","journal-title":"Stroke"},{"issue":"03","key":"ref167","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jacc.2014.03.048","article-title":"Alcohol consumption and risk of atrial fibrillation: a prospective study and dose-response meta-analysis","volume":"64","author":"S C Larsson","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"05","key":"ref168","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"R Pisters","year":"2010","journal-title":"Chest"},{"issue":"15","key":"ref169","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1136\/heartjnl-2013-304036","article-title":"Alcohol intake and prognosis of atrial fibrillation","volume":"99","author":"T F Overvad","year":"2013","journal-title":"Heart"},{"key":"ref170","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab315","article-title":"Lower risk of stroke after alcohol abstinence in patients with incident atrial fibrillation: a nationwide population-based cohort study","author":"S R Lee","year":"2021","journal-title":"Eur Heart J"},{"issue":"01","key":"ref171","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1817591","article-title":"Alcohol abstinence in drinkers with atrial fibrillation","volume":"382","author":"A Voskoboinik","year":"2020","journal-title":"N Engl J Med"},{"key":"ref172","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.2337\/dc20-2607","article-title":"Alcohol abstinence and the risk of atrial fibrillation in patients with newly diagnosed type 2 diabetes mellitus: a nationwide population-based study","volume":"44","author":"Y J Choi","year":"2021","journal-title":"Diabetes Care"},{"issue":"08","key":"ref173","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.hrthm.2011.03.038","article-title":"Smoking and incidence of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) study","volume":"8","author":"A M Chamberlain","year":"2011","journal-title":"Heart Rhythm"},{"key":"ref174","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ijcard.2016.05.013","article-title":"Association of smoking with the risk of incident atrial fibrillation: a meta-analysis of prospective studies","volume":"218","author":"W Zhu","year":"2016","journal-title":"Int J Cardiol"},{"issue":"05","key":"ref175","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.hrthm.2021.01.016","article-title":"Predictors of ischemic stroke for low-risk patients with atrial fibrillation: a matched case-control study","volume":"18","author":"S Kwon","year":"2021","journal-title":"Heart Rhythm"},{"issue":"11","key":"ref176","first-page":"10","article-title":"Smoking cessation after diagnosis of new-onset atrial fibrillation and the risk of stroke and death","volume":"10","author":"S R Lee","year":"2021","journal-title":"J Clin Med"},{"key":"ref177","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ijcard.2018.12.048","article-title":"Long-term exposure of fine particulate matter air pollution and incident atrial fibrillation in the general population: a nationwide cohort study","volume":"283","author":"I S Kim","year":"2019","journal-title":"Int J Cardiol"},{"issue":"01","key":"ref178","doi-asserted-by":"crossref","first-page":"16324","DOI":"10.1038\/s41598-020-73537-8","article-title":"Long-term PM2.5 exposure and the clinical application of machine learning for predicting incident atrial fibrillation","volume":"10","author":"I S Kim","year":"2020","journal-title":"Sci Rep"},{"issue":"08","key":"ref179","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1161\/CIRCULATIONAHA.108.785626","article-title":"Physical activity and incidence of atrial fibrillation in older adults: the cardiovascular health study","volume":"118","author":"D Mozaffarian","year":"2008","journal-title":"Circulation"},{"issue":"01","key":"ref180","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijcard.2006.03.034","article-title":"Effects of short-term exercise training on symptoms and quality of life in patients with chronic atrial fibrillation","volume":"116","author":"F Hegbom","year":"2007","journal-title":"Int J Cardiol"},{"issue":"06","key":"ref181","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.ahj.2011.09.013","article-title":"A randomized study of the effects of exercise training on patients with atrial fibrillation","volume":"162","author":"P S Osbak","year":"2011","journal-title":"Am Heart J"},{"issue":"05","key":"ref182","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.mayocp.2016.03.002","article-title":"Exercise capacity and atrial fibrillation risk in veterans: a cohort study","volume":"91","author":"C Faselis","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"01","key":"ref183","doi-asserted-by":"crossref","first-page":"13270","DOI":"10.1038\/s41598-019-49686-w","article-title":"Physical activity and risk of atrial fibrillation: a nationwide cohort study in general population","volume":"9","author":"M N Jin","year":"2019","journal-title":"Sci Rep"},{"issue":"09","key":"ref184","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/europace\/eup197","article-title":"Is the risk of atrial fibrillation higher in athletes than in the general population? A systematic review and meta-analysis","volume":"11","author":"J Abdulla","year":"2009","journal-title":"Europace"},{"issue":"06","key":"ref185","doi-asserted-by":"crossref","first-page":"e1003659","DOI":"10.1371\/journal.pmed.1003659","article-title":"Association between exercise habits and stroke, heart failure, and mortality in Korean patients with incident atrial fibrillation: a nationwide population-based cohort study","volume":"18","author":"H J Ahn","year":"2021","journal-title":"PLoS Med"},{"issue":"14","key":"ref186","first-page":"10","article-title":"Exercise and the risk of dementia in patients with newly diagnosed atrial fibrillation: a nationwide population-based study","volume":"10","author":"J Lim","year":"2021","journal-title":"J Clin Med"},{"issue":"10","key":"ref187","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/j.mayocp.2020.07.028","article-title":"The prognostic value of electrocardiogram at presentation to emergency department in patients with COVID-19","volume":"95","author":"P Elias","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"09","key":"ref188","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.jacep.2021.02.009","article-title":"Atrial fibrillation in patients hospitalized with COVID-19: incidence, predictors, outcomes, and comparison to influenza","volume":"7","author":"D R Musikantow","year":"2021","journal-title":"JACC Clin Electrophysiol"},{"key":"ref189","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejim.2021.04.023","article-title":"Incident atrial fibrillation and its risk prediction in patients developing COVID-19: a machine learning based algorithm approach","volume":"91","author":"G YH Lip","year":"2021","journal-title":"Eur J Intern Med"},{"issue":"11","key":"ref190","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/jcm10112490","article-title":"Prevalence and impact of atrial fibrillation in hospitalized patients with COVID-19: a systematic review and meta-analysis","volume":"10","author":"G F Romiti","year":"2021","journal-title":"J Clin Med"},{"issue":"23","key":"ref191","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1016\/j.jacc.2020.04.031","article-title":"COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review","volume":"75","author":"B Bikdeli","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"ref193","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwab021","article-title":"Anticoagulation therapy in non-valvular atrial fibrillation in the COVID-19 era: is it time to reconsider our therapeutic strategy?","author":"P E Papakonstantinou","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"ref194","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3389\/fphar.2020.01275","article-title":"Evaluation of Remote pharmacist-led outpatient service for geriatric patients on rivaroxaban for nonvalvular atrial fibrillation during the COVID-19 pandemic","volume":"11","author":"X Li","year":"2020","journal-title":"Front Pharmacol"},{"issue":"07","key":"ref195","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1055\/s-0040-1713152","article-title":"Pharmacological agents targeting thromboinflammation in COVID-19: review and implications for future research","volume":"120","author":"B Bikdeli","year":"2020","journal-title":"Thromb Haemost"},{"key":"ref197","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ijcard.2020.12.024","article-title":"Reduction in all-cause mortality in COVID-19 patients on chronic oral anticoagulation: a population-based propensity score matched study","volume":"329","author":"G Denas","year":"2021","journal-title":"Int J Cardiol"},{"issue":"16","key":"ref198","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.jacc.2020.08.041","article-title":"Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19","volume":"76","author":"G N Nadkarni","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"ref199","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2021.06.014","article-title":"Direct-acting oral anticoagulants use prior to COVID-19 diagnosis and associations with 30-day clinical outcomes","volume":"205","author":"J M Rivera-Caravaca","year":"2021","journal-title":"Thromb Res"},{"issue":"15","key":"ref200","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.jacc.2021.02.035","article-title":"Recent randomized trials of antithrombotic therapy for patients with COVID-19: JACC state-of-the-art review","volume":"77","author":"A H Talasaz","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"09","key":"ref201","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa2105911","article-title":"Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19","volume":"385","author":"P R Lawler","year":"2021","journal-title":"N Engl J Med"},{"issue":"16","key":"ref203","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1001\/jama.2021.4152","article-title":"Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial","volume":"325","author":"P Sadeghipour","year":"2021","journal-title":"JAMA"},{"key":"ref204","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/S0140-6736(21)01203-4","article-title":"Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial","volume":"397","author":"R D Lopes","year":"2021","journal-title":"Lancet"},{"issue":"08","key":"ref205","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1055\/a-1535-8807","article-title":"The COVID-19 pandemic and the need for an integrated and equitable approach: an international expert consensus paper","volume":"121","author":"G T Gerotziafas","year":"2021","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref206","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/ehjqcco\/qcab061","article-title":"Targeted atrial fibrillation (AF) detection in COVID-19 vaccination clinics","volume":"7","author":"G A Ford","year":"2021","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"08","key":"ref207","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1055\/a-1499-0119","article-title":"SARS-CoV-2 vaccine and thrombosis: an expert consensus on vaccine-induced immune thrombotic thrombocytopenia","volume":"121","author":"I Elalamy","year":"2021","journal-title":"Thromb Haemost"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0041-1739411.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T11:09:33Z","timestamp":1699787373000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0041-1739411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,13]]},"references-count":203,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2022,1,17]]},"published-print":{"date-parts":[[2022,1]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0041-1739411","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,13]]}}}